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96may improve cognition and reduce dementia risk. The neuroprotective effects of these dietary
components indicate that they are likely to be additive and potentially synergistic.
Methods: The Cognitive Ageing, Nutrition and Neurogenesis trial hypothesizes that an intervention
comprising long-chain n-3 polyunsaturated fatty acids (docosahexaenoic acid and eicosapentaenoic
acid) and cocoa flavan-3-ols (n-3 FLAV) will mitigate the cognitive decline anticipated to naturally
occur over 1 year in older adults with mild cognitive impairment or subjective memory impairment.
A double-blinded, placebo-controlled parallel design is used. Two hundred fifty-nine adults
(aged 55 years) with mild cognitive impairment or subjective memory impairment were recruited
and randomized to a control or n-3 FLAV group (1.5 g docosahexaenoic acid1 eicosapentaenoic acid
and 500 mg n-3 FLAV daily) for 12 months. Cognitive performance was measured three times
over the 1-year intervention, at 0 (baseline), 3, and 12 months. The primary end point is
hippocampus-sensitive cognitive function (e.g., number of false-positives on the Picture Recognition
Task of the Cognitive Drug Research test battery). Secondary outcomes include additional cognitive
measures, brain atrophy and blood flow (assessed bymagnetic resonance imaging), vascular function,
circulating biomarkers of cardiovascular and cognitive health, gut microflora speciation and
metabolism, red blood cell fatty acid status, and urine flavan-3-ol metabolites. The intervention
arms were matched for sex and apolipoprotein E4 status to allow retrospective exploratory analysis
of the impact of these variables on response to intervention.est: The research was funded in part by Abbott
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178Results: Screening began in 2015, with all baseline visits completed in March 2017. The
intervention was finished in March 2018.
Discussion: Cognitive Ageing, Nutrition and Neurogenesis aims to identify an effective diet-based
intervention to prevent or delay cognitive impairment in cognitively at-risk individuals, which could
ultimately contribute to a reduced population burden of dementia.
Clinicaltrials.gov: NCT02525198.
 2018 Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).179
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2311. Background and rationale
Although there is evidence of a decrease in incidence in
early old age, the number of dementia cases is set to
approximately double every 20 years, increasing to
115 million by 2050 [1]. Lifestyle strategies to preserve or
improve memory and cognition would provide significant
health, social, and economic benefits. In the UK, delaying
dementia onset by 2 or 5 years would result in 19% and
33% reductions in prevalence, respectively, by 2050 with a
much lower prevalence of severe dementia [2]. Similarly,
it has been estimated that a 2-year delay in onset would
reduce the global incidence of dementia by 22% by 2047
[3], resulting in 25 million fewer cases [1,3–5]. Even
greater benefits would be observed in “at-risk” and
prodromal population subgroups, such as apolipoprotein
E4 (APOE4) carriers, and those with existing mild
cognitive impairment (MCI) or subjective memory
impairment (SMI; self-diagnosed and defined as noticing a
decline in memory over the previous 2–3 years) [4–7].
Those with MCI and SMI, although experiencing
metabolic brain changes and some loss of function, are
unlikely to have yet undergone the same degree of
macroscopic neural cell death in brain regions implicated
in the pathogenesis of dementias as those with a confirmed
diagnosis [8,9], and thus may be more responsive to
interventions and experience some reversal of cognitive
decline [10].
To date, the reductionist approach to nutritional
interventions has often focused on the impact of individual
foods, food groups, or dietary components on cognitive
function. The neural processes involved in cognitive decline
are complex and multifactorial. Therefore, combination
treatments with dietary compounds that target multiple
physiological and molecular mechanisms are likely to
have the most realistic chance of affecting cognition [11,12].
Substantial data from prospective cohort studies and
animal models provide evidence for the individual
neurophysiological effects of the fish-derived long-chain
n-3 polyunsaturated fatty acids (LC n-3 PUFAs),
eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA), as well as flavan-3-ols (n-3 FLAV; plant bioactives
found in cocoa, teas, and berries). In a prospective study
with 3.9 years of follow-up, higher total n-3 PUFA andFLA 5.5.0 DTD  TRCI177_proof DHA intakes were associated with a lower relative risk
of Alzheimer’s disease (AD; relative risk, 0.3; 95% CI,
0.1–0.9, in the highest quintile of DHA intake) [13], with
subsequent observations of associations between plasma
EPA and DHA status and dementia risk [14,15] and
cognitive decline [15,16]. In the Women’s Health Initiative
Memory Study, EPA and DHA status was associated with
larger total brain and hippocampal volumes, which was
confirmed in more recent investigations [17,18]. The
limited number of large-scale interventions with LC n-3
PUFA, predominantly in those with incident dementia, has
produced mixed findings [19,20] and highlights the need
to take a combined intervention approach with a focus on
preclinical individuals.
Flavonoids are plant bioactives, with considerable
evidence supporting their neurocognitive benefits. In the
PAQUID cohort, which included 1640 adults free of
dementia aged 65 years or older, higher total flavonoid
intake was associated with better cognitive performance
at baseline and a better performance trajectory over a
10-year period Q[21]. An association between higher cocoa
flavan-3-ol (which represents the focus of the current
Cognitive Ageing, Nutrition and Neurogenesis [CANN]
trial) consumption and performance on various cognitive
instruments has been repeatedly observed [22–24], with
Sorond and colleagues [24] also reporting an association
with neurovascular coupling, which refers to the close
functional and spatial relationship between cerebral blood
flow (CBF) and neuronal activity.
Rodent studies provide substantial mechanistic insight
[25–28] into the pleiotropic impact of EPA 1 DHA and
n-3 FLAV, and suggest that they likely confer additive and
potentially synergistic benefits. Neuronal membranes are
particularly enriched in DHA, with DHA supplementation
increasing DHA availability for cell membrane synthesis
in neurogenesis, neurite outgrowth, and synaptogenesis
[26]. Furthermore, DHA decreases neuroinflammation,
mediated by the 15-lipoxygenase DHA derivative,
neuroprotectin D1 [29]. n-3 FLAV promote neuronal
survival, spine density formation, synaptic plasticity, and
the production of brain-derived neurotrophic factor
[25,27]. They are also anti-inflammatory and reduce the
production of amyloid beta (40–42) peptides [30]. Through4 September 2018  5:34 pm  ce











































































306the enhancement of antioxidant enzyme activities, n-3 FLAV
are also likely to indirectly reduce the oxidation of
membrane DHA [31]. Finally, EPA 1 DHA plus n-3
FLAV may confer cognitive benefits through their impact
on vascular function and CBF [32–35].
The CANN trial is designed to examine for the first time
the impact of LC n-3 PUFA plus n-3 FLAV on cognition,
brain atrophy and blood flow, and biomarkers of cognitive
and cardiovascular function, over a 1-year period in older
adults with SMI or MCI. It aims to identify an intervention
to promote cognitive health and reduce dementia risk, which



































































3532. Design and methodology
2.1. Overview
This study uses a double-blinded, placebo-controlled
parallel design. There are two recruitment sites: the
University of East Anglia (Norwich, UK) and the Swinburne
University of Technology (Melbourne, Australia), with
magnetic resonance imaging (MRI) images analyzed
centrally at the University of Illinois (Urbana Champaign,
Urbana, IL). After a telephone screening, postal
questionnaires, and an on-site screening visit (V1),
participants are asked to attend three clinical visits (V2,
V3, and V4) at 0 (baseline), 3, and 12 months (Fig. 1). At
these visits, participants undergo cognitive assessment and
provide a number of clinical measures and biological
samples.
2.2. Ethical conduct of the study
The conduct, evaluation, and documentation of this study
abide by Good Clinical Practice guidelines and the guiding
principles of the Declaration of Helsinki. The study was
approved by Bellberry Human Research Ethics Committee
(Study ID 2015-03-227) and Swinburne University Human
Research Ethics Committee (SHR Project 2015-208) for
the Swinburne University of Technology site and the
National Research Ethics Service Committee (Study ID
14/EE/0189) for the University of East Anglia site. All
participants provided informed signed consent before
participating.
2.3. Intervention products
Participants are asked to consume 3! 1 g oil capsules
(Captek Soft Gel International, Cerritos, CA) and 33 g of
chocolate drops of either test or control products daily for
12 months, and to take the products with the main meal
of the day (as there is some evidence of reduced EPA and
DHA bioavailability in the fasting state relative to a
fat-containing meal [36]). The test capsules provided fish
oil (EPAX AS, Aalesund, Norway) delivering 1.1 g DHA
and 0.4 g EPA per day. The control capsules contained aFLA 5.5.0 DTD  TRCI177_proof blend of 80% palm oil and 20% corn oil (Cargill and
Hybco, Los Angeles, CA) that provides a fatty acid (FA)
composition typical of a UK or Australian diet. Both the
test and control capsules contained 1% lemon oil, to
provide a lemon flavor to maintain study blinding, and
1% mixed tocopherols for stability of the study oils. The
test chocolate drops (33 g) contained cocoa powder
(Acticoa; Barry Callebaut, Lebbeke, Belgium) providing
500 mg of n-3 FLAV, ranging from monomers to decamers
(i.e., degrees of polymerization from 1 to 10). The test
chocolate drops delivered 158 calories, 262 mg
theobromine, and 30 mg caffeine. The control chocolate
drops (33 g; Blommer Chocolate Co, Chicago, IL) were
similar in size and color and delivered 38 mg n-3 FLAV,
160 calories, 64 mg theobromine, and 5.4 mg caffeine.
The chocolates were matched for macronutrient
composition. The doses of n-3 FAs and n-3 FLAV have
been selected to be (1) physiologically relevant, equivalent
to half a portion of oily fish and two portions of enriched
cocoa per day, and (2) bioactive based on prospective
epidemiologic data, as described previously.4 September 2018  5:34 pm  ce
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427At V2, participants are provided with their intervention
products for the next 3 months, and at V3 participants
receive the remaining 9 months’ worth of supply. They
are provided with a log to record the time at which the
intervention products are consumed each day and are asked
to return their empty chocolate sachets and oil capsule
bottles to the research team to monitor compliance. The
threshold for categorization as adherent to the intervention
is set at 80%. Participants are contacted on a monthly basis
by telephone to promote compliance and to check for any
































Participants allocated to the intervention arm will
perform significantly better than the control group on
hippocampus-sensitive measures of cognitive function,
namely the number of false-positives on the Picture
Recognition Task of the Cognitive Drug Research (CDR)
test battery and performance on the iPosition task.
2.4.2. Secondary hypotheses
1. Participants allocated to the intervention arm will
perform better in the composite cognitive domains
of attention, working memory, episodic memory, and
speed of retrieval from memory, relative to the control
intervention.
2. Participants allocated to the intervention arm and
carrying the APOE4 allele will show a better
cognitive response to intervention relative to APOE4
noncarriers.
3. Cognitive response to intervention will be associated
with speciation of the gut microbiota.
4. Cerebrovascular blood flow and hippocampal
volume, as assessed by MRI, will be greater in the
intervention group compared with the control group
at 12 months.Table 1
Overview of CANN inclusion criteria
Type Criterion
General Males and females, aged 55 y and older
Diagnosis of MCI or SMI with no indication of clinical
Willing and able to provide written informed consent, an
and to comply with all study procedures
Fluent in written and spoken English
In good general health, including blood biochemical, he
Normal or corrected-to-normal vision and hearing
Stable use of any prescribed medication for at least 4 wk
MRI (50% of cohort) Aged from 55 to 85 y
Abbreviations: CANN, Cognitive Ageing, Nutrition and Neurogenesis; MCI, mi
memory impairment.
FLA 5.5.0 DTD  TRCI177_proof 2.5. Participant inclusion criteria
All inclusion and exclusion criteria are detailed in
Tables 1 and 2, respectively.
2.6. Sample size
The sample size estimate was based on the predicted
impact of 1.5 g LC n-3 PUFA (1.1 g DHA and 0.4 g EPA)
and 500 mg cocoa n-3 FLAV administered daily for
12 months. This combination has not been previously used
in any intervention study and therefore a power calculation
using directly relevant data was not possible Q. For LC n-3
PUFA, the most relevant previous study [37] administered
1.3 g DHA and 450 mg EPA for 12 months to MCI
participants. Effects sizes, estimated from partial hs,
were as follows: for a delayed recall task, hp2 5 0.121
(approx. d 5 0.74); for the Digit Span task, hp2 5 0.254
(approx. d 5 1.17); and for a visual reproduction task,
hp2 5 0.114 (approx. d 5 0.72). The computed d for a
composite memory score (presented as a z-score) was
1.17. Regarding flavonoids, Desideri and colleagues
administered 990 or 520 mg of n-3 FLAV, with a Cohen’s
d of 1.64 reported for the lower dose, which closely
corresponds to that in our trial [22]. The outcome in this
study was a composite cognitive score. The consumption
of concord grape juice by MCI patients was associated
with Cohen’s f of 0.28 for verbal learning, and 0.33 for
delayed recall (i.e., medium effect sizes) [38,39].
On the basis of the range of these effect sizes, we conser-
vatively base our power calculation on a medium effect size,
that is, Cohen’s d of approximately 0.5, which generates a
sample size of 108 per group for a two-arm trial, with 90%
power to detect a significant change at the 5% probability
level. The group sizes of 120 assumed a 10% attrition rate.
2.7. Study measures
Table 3 lists all the study procedures by visit.
2.8. Screening
The screening process was conducted in two phases.dementia or depression
d verbal informed consent for the telephone screening eligibility,
matologic, and urinalysis results within the normal range at screening (V1)
before baseline (V2)
ld cognitive impairment; MRI, magnetic resonance imaging; SMI, subjective



















Overview of CANN exclusion criteria
Type Criterion
General and health-related Diagnosis of AD or other form of dementia, or significant neurologic disorder
Parent or sibling who developed dementia before the age of 60 y
Past history/MRI evidence of brain damage, including significant trauma, stroke, or other serious neurologic disorder, including
loss of consciousness for .24 h
Clinically diagnosed psychiatric disorder likely to affect the cognitive measures
Existing gastrointestinal disorder likely to impact on the absorption of flavonoids and FAs (e.g., celiac disease, Crohn disease,
irritable bowel syndrome)
Major cardiovascular event (e.g., myocardial infarction or stroke) in the last 12 mo
Carotid stents or severe stenosis
Any other existing medical condition likely to affect the study measures (as judged by the trial’s clinical advisor)
Uncontrolled hypertension (SBP .160 mm Hg or DBP .100 mm Hg)
BMI 40 kg/m2
Current or ex-smoker who stopped ,6 mo ago
Prescribed medications likely to influence the study measures (as judged by the clinical advisor)
Participated in any other study involving an investigational product in the last 4 wk
Drugs, alcohol, smoking History of alcohol or drug dependency within the last 2 y
Taking antipsychotics, high-dose antidepressants (as judged by the clinical advisor), cholinesterase inhibitors, benzodiazepines,
anticonvulsants, illicit drugs/other drugs that can influence psychometric test results. Statins and NSAIDs are not exclusionary
but use must be stable for at 2 mo before baseline (V2)
Subjective reporting of sedation from any prescribed medication, that is, night sedation (Z drugs)/pain relief medication
Dietary-related Known allergy to fish or any other component of the intervention products
Taking flavonoid-containing supplements
Taking fish oils or other n-3 FA-rich supplements
High n-3 FA status (determined by red blood cell n-3 FA index .6% [EPA 1 DHA] as a % of total FAs)
High flavonoid intake (.15 portions of flavonoid-rich foods per day)
MRI (50% of cohort) Presence of metal implants
Claustrophobia
Abbreviations: AD, Alzheimer’s disease; BMI, body mass index; CANN, Cognitive Ageing, Nutrition and Neurogenesis; DBP, diastolic blood pressure;
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FA, fatty acid; MRI, magnetic resonance imaging; NSAIDs, nonsteroidal anti-inflammatory drugs;
SBP, systolic blood pressure.


























































































































The CANN Telephone Screening Questionnaire assesses
general adherence to the inclusion and exclusion criteria and
provides an assessment of flavonoid, oily fish, and fish oil
supplement intake. It also includes the Geriatric Depression
Scale–short form (GDS-15) [40], the Modified Telephone
Interview for Cognitive Status [41], and questions that serve
as a basis for distinguishing SMI fromMCI (confirmed at the
on-site screening visit [V1]) (Fig. 2). Participants who
passed the telephone screening were invited to take part in
an in-person screening (V1) within 3 months. The
following questionnaires were mailed out for completion
before V1: the Functional Activities Questionnaire, Memory
Functioning Questionnaire, NEO Personality Inventory-Five
Factor Inventory, Hospital Anxiety and Depression Scale,
and the CANN Study General Health and Lifestyle
Questionnaire (see Appendix A).
2.8.2. On-site screening visit (V1)
Written consent was obtained from all participants at V1
after adequate explanation of the aims, methods, objectives,
and potential hazards of the study. Date of birth, gender, total
years of education, highest level of education, medical and
surgical history (including allergies or food intolerances),FLA 5.5.0 DTD  TRCI177_proof and use of any concomitant medications were recorded in
the case report form. Measurements of height and weight
were taken for the calculation of body mass index (BMI)
(with a BMI40 kg/m2 being exclusionary). Blood pressure
(BP) was taken three times and the average of the second and
third readings used as the BP value. If the average exceeded
either 160 systolic BP or 100 diastolic BP (mm Hg), the
participant was deemed ineligible for trial entry, and advised
to consult with their general practitioner. A fasted blood
sample was collected for APOE genotyping, red blood cell
(RBC) FA analysis, full blood count, and liver and kidney
function test (see Appendix A). Individuals with an RBC
DHA level of .6% of total FAs, or a high intake of oily
fish or flavonoid-rich foods (see Appendix A) were
precluded from participating, on the basis that they had a
high habitual intake of DHA and flavonoids, which are
unrepresentative of the normal population and are unlikely
to be responsive to intervention. Further details are given
in Appendix A.
2.8.3. Assessment of cognitive status
After a standard breakfast, participants completed a
neuropsychological test battery to confirm MCI or SMI




Overview of CANN study testing procedures and sample collections by time point
Study event Screening (V1) Baseline (V2) 3 mo (V3) 12 mo (V4)
CANN Telephone Screening Questionnaire X
Functional Activities Questionnaire X X
Memory Functioning Questionnaire X X
NEO Personality Inventory-Five Factor Inventory X
Hospital Anxiety and Depression Scale X
General Health and Lifestyle Questionnaire X
Informed Consent X
Adverse events X X X X
Montreal Cognitive Assessment X X X X
Test of Premorbid Functioning X
California Verbal Learning Test-II X
Logical Memory I and II X
Boston Naming Test X
Figure Copy task X
Digit Span Task—Forward and Backward X
Trail Making Test—A and B X
International Physical Activity Questionnaire X X X
Profile of Mood States X X X
Food Frequency Questionnaire X X X
Cognitive Drug Research Test Battery [Practice] X X X
iPosition X X X
Verbal Fluency Test X X
Vascular function* X X X
Plasma Biomarkersy X X X
PBMC collection X X X
Magnetic resonance imagingz X X
Magnetoencephalographyx X X X
Blood sample for genotyping X
Urine collection X X X
Stool collection X X X
Abbreviations: CANN, Cognitive Ageing, Nutrition and Neurogenesis; PBMC, blood peripheral blood mononuclear cell.
NOTE. Red blood cell fatty acid status will be obtained as a measure of response to intervention.
*Resting blood pressure, central pressure and wave reflection, carotid/cerebral pulse wave velocity (plus ambulatory 24 hour blood pressure at the University
of East Anglia, Norwich, UK, only).
yLipids, glucose, inflammatory markers, and brain-derived neurotrophic factor.
zDiffusion tensor imaging, arterial spin labeling, magnetic resonance spectroscopy (in 50% of the trial participants).
xAt the Swinburne University of Technology, Melbourne, Australia, only.


























































































































719Montreal Cognitive Assessment (MoCA) [42], California
Verbal Learning Test-II [43], Boston Naming Test [44],
Figure Copy task [45], Digit Span task (Forward and
Backward) [46], Trail Making Test (A and B) [47], Test of
Premorbid Functioning [48], CDR test battery [49], and
iPosition task [50,51] (see Appendix B).
For classification of MCI status, criteria developed by the
National Institute on Aging-Alzheimer’s Association
workgroup [52] are used (Fig. 2). If a respondent feels that
(1) their memory has declined in the last 2 to 3 years, and
this is of concern to them, a diagnosis of MCI is possible
depending on evidence of (2) preservation of independence
in functional abilities (Functional Activities Questionnaire
score ,6), (3) absence of dementia (MoCA score 18),
and (4) depression (GDS-15 score ,10). Finally,
impairment in one or more cognitive domains that are
greater than would be expected given a person’s age and
education is required for MCI status (1 standard deviation
[SD] below the mean on any of the following
neuropsychological tests: memory, California VerbalFLA 5.5.0 DTD  TRCI177_proof Learning Test-II or Logical Memory I or II of the Wechsler
Memory Scale–Revised; language, Boston Naming Test;
visuospatial function, the Figure Copy task of the
Repeatable Battery for the Assessment of Neuropsycholog-
ical Status; attention, the Digit Span task (Forward or
Backward) of the Wechsler Adult Intelligence Scale, third
edition; and executive function, the Trail Making Test
(A or B) (see Appendix C). Participants who satisfy
aforementioned criteria (1) to (4), but do not score 1 SD
below the mean on any neuropsychological test are classified
as SMI.
All eligible participants at V1 are sent the EPIC Food
Frequency Questionnaire, the International Physical
Activity Questionnaire, and the Profile of Mood States
(see Appendix D).2.9. Randomization of participants to groups
In total, 259 participants were recruited (by means of



















Fig. 2. Flowchart for classifying mild cognitive impairment (MCI) and subjective memory impairment (SMI) status.


























































































































841articles, and radio show participation) and randomized to arm
A or arm B (Fig. 3) using a randomization algorithm
(Covariate Adaptive Randomization software [53]), with
groups stratified by APOE genotype (E4 carrier vs. non-E4
carrier), sex (male vs. female), and cognitive status (SMI vs.
MCI).
2.9.1. Clinical visits V2 to V4
The neuropsychological test battery for V2 to V4
comprises the CDR test battery, MoCA, Delis-Kaplan
Executive Function System, Verbal Fluency Test (V2 and
V4 only), and iPosition task (Appendix B). Participants
provide an overnight fasted blood sample, a urine sample
analyzed for flavan-3-ol metabolite profile, and a fecalFLA 5.5.0 DTD  TRCI177_proof sample to determine speciation and metabolism of the gut
microbiota. Cardiovascular assessments, including aortic
and 24-hour ambulatory BP and carotid-femoral pulse
wave velocity were also conducted (for full details see
Appendix E). The plasma samples will be analyzed for a
number of biomarkers of cardiovascular and cognitive
function including triglycerides, total and HDL cholesterol,
glucose, insulin, cortisol, brain-derived neurotrophic
factor, ApoE, and C-reactive protein (as a measure of
inflammation).
2.9.2. MRI and magnetoencephalography (V2 and V4)
We use a variety of magnetic resonance techniques to































































































916These include structural imaging, diffusion tensor imaging,
magnetic resonance spectroscopy, arterial spin labeling,
and magnetoencephalography. Diffusion tensor imaging
provides a measure of white matter integrity that is sensitive
to MCI and AD [54]. Magnetic resonance spectroscopy is
used to measure the biochemistry of the brain and has
been used to obtain measures that are predictive of MCI
[55]. In CANN, we will measure N-acetylaspartate, creatine,
choline, glutamate, and myo-inositol as biomarkers of
neurogenic activity. Arterial spin labeling has previously
been used to monitor changes in CBF in patients with AD
and MCI [56]. Protocol details for each imaging modality






Data will be analyzed using SAS (ver. 9.4; SAS Institute,
Cary, NC) and SPSS software (ver. 22.0; SPSS Inc, Chicago,Fig. 3. Flowchart of participation in the Cognitive Age
FLA 5.5.0 DTD  TRCI177_proof IL). Summary statistics (n, mean, median, SD, standard error
of the mean, range) will be generated and change from
baseline scores for treatment arms A and B, on all outcome
measures, will be calculated by subtracting the baseline
score (V2) from those at V3 and V4. Group comparisons
will be performed using independent t tests and analysis of
variance as appropriate Q, and correlation analyses will be
conducted using Pearson’s r.4. Results
Fig. 3 shows the flow of participants throughout the study
period. After the initial telephone screening (N 5 637),
prospective participants were invited to the on-site screen
(V1, n 5 351) within 3 months; those who were deemed
eligible were then allocated to the intervention or control
arm (n 5 259) and invited back for their first clinical visit
(V2) within 3 months. Two hundred forty-six participantsing, Nutrition and Neurogenesis (CANN) study.





















































Age (y) 66.1 6 6.5 65.7 6 6.2 64.8 6 6.6
Gender
Male 148 55 51
Female 203 70 70
Cognitive status
SMI 201 71 71
MCI 140 54 50
APOE4 carrier
Yes 96 35 34
No 242 90 87
MoCA score 27.0 6 2.4 27.0 6 2.3 27.1 6 2.3
Years of education 14.5 6 3.8 14.9 6 4.2 14.1 6 3.2
IQ 115.6 6 9.4 116.0 6 9.8 115.3 6 9.3
BMI 27.3 6 6.1 27.1 6 4.1 26.6 6 4.4
RBC n-3 FA index 5.2 6 1.3 4.7 6 1.0 4.7 6 0.8
SBP (mm Hg) 139.7 6 15.3 138.1 6 14.32 138.8 6 14.9
DBP (mm Hg) 81.0 6 9.0 81.8 6 8.8 80.5 6 8.5
Abbreviations: APOE4, apolipoprotein E4; BMI, body mass index; DBP,
diastolic blood pressure; IQ, intelligence quotient; MCI, mild cognitive
impairment; MoCA, Montreal Cognitive Assessment; RBC n-3 FA index,
red blood cell n-3 fatty acid index (5% of total fatty acid as
eicosapentaenoic acid plus docosahexaenoic acid); SBP, systolic blood
pressure; SMI, subjective memory impairment.
NOTE. Values are numbers or means 6 standard deviation. There were
no significant differences between the two treatment arms for any parameter
(all P . .05). On analysis of study dropouts versus project completed,
no significant differences were found in any variable listed in Table
(all P . .05), with the exception of gender (P 5 .003), with the dropouts
being significantly more likely to be female.





































































































1064completed V2, with a mean (6SD) age and BMI of
66.5 6 6.5 years and 268.9 6 4.3 kg/m2, respectively.
In total, 57% of the cohort was female and 28%






















CANN will investigate if an intervention with a
combination of dietary components can prevent or delay
cognitive decline in older adults at increased risk of
dementia. The choice of outcome measures has long been
a subject of debate for randomized control trials targeting
dementia risk. Given that the focus in CANN is on
prevention rather than on conversion of SMI/MCI to AD,
sensitive neurocognitive tests were used to test efficacy
with false-positives in the Picture Recognition Task and
the iPosition task chosen as highly sensitive indices of
hippocampus integrity and function.
The inclusion of structural and functional MRI and
magnetoencephalography, along with a range of prognostic
cardiovascular assessments, such as 24-hour ambulatory
BP and pulse wave velocity, will provide insight into the
physiological basis of the impact of intervention onFLA 5.5.0 DTD  TRCI177_proof cognition. Cardiovascular health is being increasingly
recognized as an important and modifiable determinant of
neurocognitive function and dementia risk [57], influencing
perfusion, blood-brain barrier function, and brain
inflammatory and lipid status. Given the cardiovascular
benefits of LC n-3 PUFA [58] and n-3 FLAV [59], improved
cardiovascular function is likely to underlie any observed
cognitive benefits.
A further design strength is the use of RBC FA status (n-3
index) as an exclusionary criterion. Individuals with a total
RBC n-3 index of .6% were ineligible on the basis that
they are unrepresentative of the general population. This
subgroup constitutes the “health conscious” older adult
deciles, with an EPA 1 DHA intake of about 300 mg per
day provided by fish oil supplements or at least one portion
of oily fish per week [60,61]; those with such a high baseline
status are unlikely to be responsive to additional intake.
Most previous trials have used fish oil supplements (rather
than EPA 1 DHA status) as an exclusionary criterion,
with high oily fish consumers often included, which may
have contributed to the observed lack of responsiveness to
intervention [62].
In the UK, about 60% of the population aged .55 years
are on prescribed medications, which increases to over 90%
of those aged 85 years and older [63]. The CANN trial took a
pragmatic approach to maximize population applicability,
with only those on high-dose medications directly
targeting neurologic functions precluded from participating.
For all other medications, participants were required to have
stable use for at least 2 months before the baseline
assessment.
APOE genotype is the strongest common genetic risk
factor for cognitive decline and AD, with those with
APOE3/E4 and APOE4/E4 genotypes at a 4- and 16-fold
increased risk of AD relative to the wild-type APOE3/E3
genotype [64]. There is accumulating evidence that part of
the neurologic dysfunction in APOE4 carriers is mediated
by altered DHA metabolism, which in healthy and
prodromal individuals could be mitigated by increased
DHA intake and status. Although not fully powered to
establish APOE4 ! treatment interactions, APOE4 carrier
status was used to randomize the participants to the
intervention arm, and an exploratory analysis was
conducted to assess response to intervention according to
the genotype.
Given the ever-increasing population burden of
dementias, the lack of effective therapeutics, and the large
impact on population prevalence of even modest delays in
disease onset, the outcomes of the CANN trial are of
substantial public health relevance.Supplementary data
Supplementary data related to this article can be found at


































































































1. Systematic review: Search of PubMed and Web of
Science databases for articles on dietary interven-
tions for cognitive decline and/or dementia,
including the terms “cognition,” “dementia,” “Alz-
heimer’s,” “mild cognitive impairment,” “subjective
memory impairment,” “omega-3 fatty acids,” “n-3
fatty acids,” “flavan-3-ols,” and so forth. The litera-
ture suggests long-chain n-3 polyunsaturated fatty
acid and flavonoids may improve cognition but there
are important gaps regarding their possible syner-
gistic effects.
2. Interpretation: Our trial is the first to investigate the
impact of cosupplementation with marine n-3 fatty
acid and cocoa flavan-3-ols on cognition and brain
structure/function (by magnetic resonance imaging)
in older adults at risk of dementia. Delaying onset by
2 to 5 years would reduce population burden in the
UK by 19% to 33% by 2050, respectively.
3. Future directions: Future studies should explore the
effects of the timing (within the healthy-to-
advanced dementia disease trajectory) of interven-
tion with flavan-3-ols in producing the maximum
cognitive benefits and also to examine response to
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